RPG Life Sciences Limited
NSE:RPGLIFE.NS
2057.65 (INR) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 5,820.5 | 5,128.1 | 4,371.6 | 3,834 | 3,691.5 | 3,239.2 | 3,371.5 | 3,062.7 | 2,789.2 | 2,422.7 | 2,353.3 | 2,216.4 | 1,928.2 | 1,841.898 | 1,598.474 | 1,404.726 | 1,277.209 | 1,202.853 |
| Cost of Revenue
| 1,942 | 1,708.7 | 1,502.1 | 1,376.4 | 1,277.6 | 1,100.4 | 1,146.1 | 1,058.4 | 914.4 | 846.9 | 767.5 | 764.4 | 552 | 497.228 | 465.241 | 422.571 | 391.801 | 419.311 |
| Gross Profit
| 3,878.5 | 3,419.4 | 2,869.5 | 2,457.6 | 2,413.9 | 2,138.8 | 2,225.4 | 2,004.3 | 1,874.8 | 1,575.8 | 1,585.8 | 1,452 | 1,376.2 | 1,344.67 | 1,133.233 | 982.155 | 885.408 | 783.542 |
| Gross Profit Ratio
| 0.666 | 0.667 | 0.656 | 0.641 | 0.654 | 0.66 | 0.66 | 0.654 | 0.672 | 0.65 | 0.674 | 0.655 | 0.714 | 0.73 | 0.709 | 0.699 | 0.693 | 0.651 |
| Reseach & Development Expenses
| 0 | 89.3 | 89.7 | 88.8 | 93.3 | 75 | 0.8 | 3.3 | 12.2 | 102.5 | 75.5 | 73.7 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 1,328.9 | 181.7 | 196.6 | 151.7 | 128.4 | 95 | 80.3 | 69.6 | 47.6 | 668.6 | 51.6 | 47.1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 213 | 356.2 | 322.7 | 227.6 | 201.3 | 186.1 | 224.3 | 183.8 | 131.5 | 17.7 | 121.9 | 120.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1,541.9 | 537.9 | 519.3 | 379.3 | 329.7 | 281.1 | 304.6 | 253.4 | 179.1 | 686.3 | 992.6 | 842.7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Expenses
| 0 | 48 | 29.9 | 1 | 1,642 | 3.7 | 1,658.2 | 1,571.4 | 1,538.4 | 1,546.9 | 1,573.4 | 1,373 | 1,290 | 1,112.178 | 906.327 | 812.904 | 707.154 | 568.446 |
| Operating Expenses
| 1,635.5 | 2,547.5 | 2,152.3 | 1,910.3 | 1,971.7 | 1,946.9 | 1,963.6 | 1,828.1 | 1,729.7 | 1,546.9 | 1,573.4 | 1,373 | 1,290 | 1,112.178 | 906.327 | 812.904 | 707.154 | 568.446 |
| Operating Income
| 2,292.3 | 881 | 707.4 | 536.6 | 429.5 | 191.9 | 261.8 | 176.2 | 145.1 | 28.9 | 12.4 | 79 | 86.2 | 232.492 | 226.906 | 169.251 | 178.254 | 215.096 |
| Operating Income Ratio
| 0.394 | 0.172 | 0.162 | 0.14 | 0.116 | 0.059 | 0.078 | 0.058 | 0.052 | 0.012 | 0.005 | 0.036 | 0.045 | 0.126 | 0.142 | 0.12 | 0.14 | 0.179 |
| Total Other Income Expenses Net
| -1,113.9 | -1,018.3 | -958.1 | 38.5 | -77.7 | -41.4 | -58.2 | -34.3 | -28.9 | -42.4 | 637.3 | -100.9 | -68.6 | -57.792 | -81.392 | -86.116 | -85.249 | -115.688 |
| Income Before Tax
| 1,178.4 | 916.8 | 731.7 | 535.8 | 364.5 | 150.5 | 203.6 | 226.8 | 116.2 | 10 | 649.7 | 5.4 | 17.4 | 174.663 | 145.514 | 83.135 | 93.005 | 99.408 |
| Income Before Tax Ratio
| 0.202 | 0.179 | 0.167 | 0.14 | 0.099 | 0.046 | 0.06 | 0.074 | 0.042 | 0.004 | 0.276 | 0.002 | 0.009 | 0.095 | 0.091 | 0.059 | 0.073 | 0.083 |
| Income Tax Expense
| 301.8 | 240.4 | 216.9 | 135.8 | 74.4 | 42.4 | 69.1 | 22.2 | 5.6 | 7 | 115.7 | -38.7 | 8.9 | 47.539 | 37.551 | 17.06 | 33.47 | 16.75 |
| Net Income
| 876.6 | 676.4 | 514.8 | 400 | 290.1 | 108.1 | 134.5 | 204.6 | 116.2 | 10 | 534 | 44.1 | 8.5 | 127.124 | 107.963 | 66.075 | 59.535 | 80.375 |
| Net Income Ratio
| 0.151 | 0.132 | 0.118 | 0.104 | 0.079 | 0.033 | 0.04 | 0.067 | 0.042 | 0.004 | 0.227 | 0.02 | 0.004 | 0.069 | 0.068 | 0.047 | 0.047 | 0.067 |
| EPS
| 53 | 40.9 | 31.13 | 24.19 | 17.54 | 6.54 | 8.13 | 12.7 | 7.03 | 0.6 | 32.29 | 2.67 | 0.51 | 7.69 | 7.51 | 4.6 | 4.19 | 5.59 |
| EPS Diluted
| 53 | 40.9 | 31.13 | 24.19 | 17.54 | 6.54 | 8.13 | 12.7 | 7.03 | 0.6 | 32.29 | 2.67 | 0.51 | 7.69 | 6.54 | 4.59 | 4.19 | 5.59 |
| EBITDA
| 1,363.5 | 1,083.3 | 902.4 | 718.4 | 555.7 | 352.3 | 394.2 | 294.9 | 242.3 | 141.7 | 155 | 177.7 | 188.4 | 327.7 | 318.728 | 263.432 | 255.843 | 264.47 |
| EBITDA Ratio
| 0.234 | 0.418 | 0.203 | 0.185 | 0.163 | 0.106 | 0.118 | 0.097 | 0.09 | 0.062 | -0.222 | 0.08 | 0.098 | 0.178 | 0.199 | 0.188 | 0.2 | 0.22 |